<DOC>
	<DOCNO>NCT00064467</DOCNO>
	<brief_summary>This study Major Depressive Disorder ( MDD ) patient decrease energy , pleasure interest .</brief_summary>
	<brief_title>Lethargic Depression Study</brief_title>
	<detailed_description>A Multicenter , Double-Blind , Placebo-controlled comparison efficacy safety flexible dose extended-release bupropion ( HCl ) 300-450 mg/day placebo administer eight week treatment adult outpatient major depressive disorder include symptom decrease energy , pleasure , interest</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Lethargy</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Inclusion criterion : Primary diagnosis MDD current duration last 12 week great 2 year . Generally good health . Subject must read write level sufficient provide write informed consent . Exclusion criterion : Current past history seizure disorder . Subject primary diagnosis receive treatment panic disorder , obsessive compulsive disorder ( OCD ) , post traumatic stress disorder ( PTSD ) , acute stress disorder , Bipolar I II disorder , schizophrenia , psychotic disorder . Currently use illicit drug psychotropic drug . Patient pose current suicidal risk attempt suicide past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lethargic</keyword>
	<keyword>decrease interest</keyword>
	<keyword>decrease motivation</keyword>
	<keyword>depression</keyword>
</DOC>